News|Articles|October 26, 2023
Inside Look at Resilience’s Latest Viral Vector Manufacturing Site
Author(s)Resilience
Designed for advanced therapy manufacturing, the Marlborough, MA facility is the first new construction at Resilience. The site will produce, rest, and release viral vector drug substance (DS) and drug product (DP), for clinical and commercial use.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
BirchBioMed’s Idiopathic Pulmonary Fibrosis Treatment Receives Orphan Drug Designation
2
PharmTech Weekly News Roundup – Week of December 1, 2025
3
Why Pharma’s AI Agents Need Smaller, Domain-Specific Models First
4
FDA Deploys Agentic AI Capabilities for Agency Staff
5
